Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?

This article was originally published in The Pink Sheet Daily

Executive Summary

At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.


Related Content

Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments
Takeda’s Strategic Run Up To Nycomed
Tudorza’s Delivery System Key To Positioning For COPD Maintenance
Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly
Forest’s Solomon Holding Firm As Icahn Presses Second Consecutive Proxy Fight
Panel Pushes For “Pragmatic” Post-Marketing Study, Head-To-Head Comparison For Forest’s Aclidinium
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts